(Q51917811)

17 April 2018

title

Treatment with olanzapine, risperidone or typical antipsychotic drugs in Asian patients with schizophrenia. (English)

1 reference

17 April 2018

1 reference

1 reference

Chul Lee

1

1 reference

17 April 2018

Kuang-Hsien Wu

2

1 reference

17 April 2018

Hussain Habil

3

1 reference

17 April 2018

Yulia Dyachkova

4

1 reference

17 April 2018

Phil Lee

5

1 reference

17 April 2018

publication date

1 May 2006

1 reference

17 April 2018

Australian and New Zealand Journal of Psychiatry

published in

1 reference

17 April 2018

volume

40

1 reference

17 April 2018

issue

5

1 reference

17 April 2018

page(s)

437-445

1 reference

17 April 2018

Management of the negative symptoms of schizophrenia: new treatment options

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2006.01820.X

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2006.01820.X

Patterns and costs of antipsychotic drug use in Taiwan: 1997 to 2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2006.01820.X

Antipsychotic drug prescription for schizophrenia in East Asia: rationale for change.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2006.01820.X

The relevance of ethnic influences on pharmacogenetics to the treatment of psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2006.01820.X

Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2006.01820.X

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2006.01820.X

Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: a randomized double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2006.01820.X

Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: results of the Japan multicenter, double-blind olanzapine trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2006.01820.X

Efficacy and safety of novel antipsychotics: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2006.01820.X

Impact on cognition of the use of antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2006.01820.X

Anxious-depressive symptoms in schizophrenia: a new treatment target for pharmacotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2006.01820.X

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2006.01820.X

The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2006.01820.X

A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2006.01820.X

Risperidone olanzapine drug outcomes studies in schizophrenia (RODOS): efficacy and tolerability results of an international naturalistic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2006.01820.X

Extrapyramidal reactions in Asians

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2006.01820.X

Hyperprolactinaemia and antipsychotic therapy in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2006.01820.X

The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2006.01820.X

Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2006.01820.X

21 January 2018

Hematology and oncology

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2006.01820.X

The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2006.01820.X

Comments on "Double-Blind Comparison of Olanzapine Versus Risperidone in the Treatment of Schizophrenia and Other Psychotic Disorders" by Tran and Associates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2006.01820.X

10.1111/J.1440-1614.2006.01820.X

21 January 2018

Identifiers

DOI

1 reference

17 April 2018

1 reference

17 April 2018